Revenue: As of FY2025 Q1, the actual value is USD 940.EPS: As of FY2025 Q1, the actual value is USD -0.97.<h3>Segment Revenue</h3><ul><li>Product Test Sales: Revenue for the three months ended March 31, 2025 was $940, compared to $15,928 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: The net loss for the three months ended March 31, 2025 was - $1,635,064, compared to - $4,163,584 for the same period in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended March 31, 2025 were - $1,631,500, compared to - $4,173,976 for the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended March 31, 2025, these expenses were $1,542,042, compared to $4,123,941 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the three months ended March 31, 2025, net cash used was - $1,400,101, compared to - $1,233,050 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the three months ended March 31, 2025, net cash used was - $47,415, compared to - $69,941 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the three months ended March 31, 2025, net cash provided was $3,308,748, compared to $1,582,607 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation: For the three months ended March 31, 2025, stock-based compensation was $30,612, compared to $2,519,404 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Cardio Diagnostics Holdings, Inc. plans to develop additional products, including clinical tests for stroke, congestive heart failure, and diabetes, and expand the adoption of its products across key channels, including health systems and self-insured employers.</li><li>Non-Core Business: The company is pursuing potential strategic partnerships and acquisitions of synergistic companies.</li></ul>

CARDIO DIAGNOSTICS HOLDINGS INC C/WTS (10/25/2027) TO PUR COM | 10-Q: FY2025 Q1 Revenue: USD 940